Biotricity Inc. (BTCY)
Market Cap | 98.12M |
Revenue (ttm) | 1.96M |
Net Income (ttm) | -15.50M |
Shares Out | 37.26M |
EPS (ttm) | -0.42 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | February 26 |
Last Price | $2.55 |
Previous Close | $2.29 |
Change ($) | 0.26 |
Change (%) | 11.35% |
Day's Open | 2.63 |
Day's Range | 2.10 - 2.64 |
Day's Volume | 327,644 |
52-Week Range | 0.67 - 2.64 |
News
REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss ...
REDWOOD CITY, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed a s...
About BTCY
Biotricity, medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry technology, an integrated electrocardiogram (ECG) device and software solution. Biotricity, Inc. has a research partnership with the University of Calgary to determine the predictive value of ECG reading... [Read more...]
Industry Medical Devices | |
CEO Dr. Waqaas Al-Siddiq Ph.D. | Employees 24 |
Stock Exchange OTCMKTS | Ticker Symbol BTCY |
Financial Performance
In 2019, Biotricity's revenue was $1.42 million, an increase of 256.03% compared to the previous year's $398,200. Losses were -$11.07 million, 28.8% more than in 2018.